Lead Product(s) : LBT-SA7
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Adjuvant Capital
Deal Size : $40.0 million
Deal Type : Series A Financing
LimmaTech Biologics Adds $3 Million in Series A Second Closing Totaling $40 Million
Details : The financing will advance company’s proprietary self-adjuvanting and multi-antigen vaccine technology platform and its vaccine pipeline, including LBT-SA7 (formerly IBT-V02).
Product Name : LBT-SA7
Product Type : Vaccine
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : LBT-SA7
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Adjuvant Capital
Deal Size : $40.0 million
Deal Type : Series A Financing